| Filed On | Filing |
|---|---|
| 20 Oct 2026 |
8-K: Other Events
Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer |
| 14 Oct 2026 |
8-K: Other Events
Completion of enrollment earlier this year and expected final PanCAN grant payment this quarter mark successful completion of a key phase of Cohort 5 |
| 13 Oct 2026 |
8-K: Other Events
New method of use patent covering pelareorep as an immunotherapy for cancer has been issued in several countries, with U.S. issuance expected in the near term |
| 06 Oct 2026 | DEFA14A |
| 06 Oct 2026 |
Proxy statement: annual meeting on November 19, 2026
CEO pay $2.1M · say-on-pay vote |
| 29 Sep 2026 |
8-K: Other Events
Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy |
| 28 Sep 2026 |
8-K: Other Events
Substantially all planned REO 033 clinical sites are now activated, with multiple patients currently on study |
| 10 Sep 2026 |
8-K: Other Events
Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer |
| 18 Aug 2026 | 8-K: Other Events |
| 12 Aug 2026 | 10-Q |
| 24 Jul 2026 | 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule |
| 20 Jul 2026 | 8-K: Other Events |
| 13 Jul 2026 | 8-K: Other Events |
| 08 Jul 2026 | 8-K: Changes in Registrant's Certifying Accountant |
| 16 Jun 2026 | 8-K: Other Events |
| 03 Jun 2026 | Form 3: McAdory John Bearden, Chief Operating Officer |
| 03 Jun 2026 |
Form 4: Pisano Wayne, Director
Granted 30,000 Stock Option |
| 03 Jun 2026 |
Form 4: Rigby Jonathan, Director
Granted 30,000 Stock Option |
| 03 Jun 2026 |
Form 4: Holtham Angela, Director
Granted 30,000 Stock Option |
| 03 Jun 2026 |
Form 4: Parsons James T., Director
Granted 30,000 Stock Option |
Loading...
